April 25th 2024
Tools to educate oncology nurses and patients on the use of Mepitel film to prevent radiation dermatitis has improved the workflow around its introduction to patients with breast cancer, as well as its application and maintenance.
The Latest on Acute Lymphocytic Leukemia
View More
A Focus on Acute Myeloid Leukemia
View More
Updates in Myelodysplastic Syndromes
View More
Community Practice Connections™: What’s Next for Patients with Breast Cancer, and How Can We Effectively Optimize PARP-, HER2/3-, and TROP2-Targeted Regimens in Treatment Plans?
View More
Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
8th Annual School of Nursing Oncology™
August 10, 2024
Register Now!
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Asian Patients With HR+, HER2- Breast Cancer Have Higher Recurrence Risk
November 23rd 2020Patients from Asian countries with hormone receptor (HR)–positive, HER2-negative breast cancer may have a higher risk of disease recurrence than those from non-Asian countries, suggesting that this population may benefit from additional adjuvant treatment with abemaciclib (Verzenio).
FDA Approves Pembrolizumab Plus Chemo for TNBC
November 14th 2020The FDA granted an accelerated approval to pembrolizumab (Keytruda) plus chemotherapy for the treatment of patients with locally recurrent, unresectable or metastatic triple-negative breast cancer (TNBC) with PD-L1 expression is CPS ≥10, according to the agency.
Triple-Negative Breast Cancer Treatments Continue to Evolve
November 4th 2020Beyond single-agent chemotherapy, few effective treatment options are available for metastatic triple-negative breast cancer (TNBC), according to Candace Mainor, MD, but several approaches comprised of immunotherapy, antibody-drug conjugates (ADCs), and PARP inhibitors are shifting standards of care and eliciting impressive response rates in heavily pretreated patients.
FDA Recommends Black-Box Warning on Breast Implants
September 30th 2020Makers of breast implants should supplement their labeling to include a boxed warning about health problems that can arise from the devices, along with a patient decision checklist that highlights those concerns, according to final guidance issued today by the Food and Drug Administration.
Atezolizumab Plus Paclitaxel in Breast Cancer: FDA Issues Safety, Efficacy Alert
September 8th 2020The FDA has issued an alert to professionals, investigators, and patients that the phase 3 IMpassion131 trial (NCT03125902) failed to show the effectiveness of atezolizumab (Tecentriq) plus paclitaxel in treatment-naïve patients with inoperable locally advanced or metastatic triple-negative breast cancer.
FDA Update on Breast Implant-Associated Lymphoma, Breast Implant Illness
August 24th 2020The Food and Drug Administration (FDA) provided an update on breast-implant associated side effects that have been reported to the agency, including breast implant-associated anaplastic large cell lymphoma (BI-ALCL) and symptoms that are commonly referred to by patients as breast implant illness (BII).
HER2+ Breast Cancer Treatment Continues to Change: Expert Weighs In
August 20th 2020The HER2-positive breast cancer treatment paradigm is constantly changing, explained Debu Tripathy, MD, who cited that in less than 1 year, there have been 2 exciting drug approvals, which are tucatinib (Tukysa) and fam-trastuzumab deruxtecan-nxki (Enhertu).
AE Management and Adherence Is Key in Breast Cancer Treatment
August 1st 2020One of the most important tasks that oncology nurses face is ensuring that patients are taking their medications consistently and correctly, and that adverse events (AEs) are properly managed—specifically in those patients with breast cancer, according to Patricia Jakel, RN, MN, AOCN.
F-627 Shows Strong, Beneficial for Chemotherapy-Induced Neutropenia in Breast Cancer
July 11th 2020Efbemalenograstim alpha (F-627) has demonstrated strong and lasting benefit when used as a treatment for chemotherapy-induced neutropenia in patients with breast cancer, meeting the primary and secondary end points of a phase 3 study.
HER2+ Breast Cancer With Brain Metastases: Unmet Needs Remain
July 7th 2020Patients with metastatic HER2-positive breast cancer who later develop central nervous system (CNS) metastases comprise a large population of all patients with breast cancer, and there continue to be an unmet need for this subgroup, explained Brian Czerniecki, MD, PhD.
FDA Approves Phesgo, an In-Home Breast Cancer Treatment
June 29th 2020The FDA approved subcutaneous Phesgo – a combination of pertuzumab (Perjeta), trastuzumab (Herceptin), and hyaluronidase–zzxf – for the treatment of patients with metastatic HER2-positive breast cancer, as well as early-stage HER2-positive breast cancer, as selected by an FDA-approved companion diagnostic test.
PIK3A-Mutant Breast Cancer Shows Increased Sensitivity to PI3Kα Inhibition
June 27th 2020Patients with breast cancer who harbor multiple PIK3A-mutant tumors achieved a higher clinical benefit from PI3Kα inhibition compared with single mutant tumors according to response analysis data from the SANDPIPER trial.
Helping Breast Cancer Survivors Deal With Body Image Issues
June 19th 2020Your patient had a mastectomy and chemotherapy and is recovering on the post-op surgical oncology unit. She has 1 or 2 JPs (Jackson Pratt’s) which are drained on a prn basis and a surgical bra. The physical part of her recovery is in progress, but what about body image issues?
Expert Talks Immunotherapy for TNBC Treatment
May 16th 2020The addition of immunotherapy to the triple-negative breast cancer (TNBC) armamentarium has led to a paradigm shift and sparked an abundance of research with immuno-oncology (IO) drugs in new combinations and settings, explained Hope S. Rugo, MD.